Alpha 2.0
Login Register
» Authors » Andreas Schlicker

Andreas Schlicker

Explore the profile of Andreas Schlicker including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 40
Citations 5020
Followers 0
Related Specialties
Oncology
Biology
Cell Biology
Top 10 Co-Authors
Rene Bernards
Mario Albrecht
Thomas Lengauer
Lodewyk F A Wessels
Christoph A Schatz
Lodewyk Wessels
Ramon Salazar
Dominik Mumberg
Roderick L Beijersbergen
Bernard Haendler
Published In
Sci Rep
Mol Cancer Ther
Int J Mol Sci
Bioinformatics
Cell
Affiliations
Soon will be listed here.
Recent Articles
1.
Darolutamide in Combination with Radium-223 Exhibits Synergistic Antitumor Efficacy in LNCaP Prostate Cancer Models
Hagemann U, Schatz C, Suominen M, Schlicker A, Knuuttila M, Wilson T, et al.
Int J Mol Sci . 2025 Jan; 25(24. PMID: 39769434
Despite treatment, prostate cancer commonly progresses into castration-resistant prostate cancer (CRPC), which remains largely incurable, requiring the development of new interventions. Darolutamide is an orally administered second-generation androgen receptor inhibitor...
2.
Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling
Graham K, Lienau P, Bader B, Prechtl S, Naujoks J, Lesche R, et al.
Cell Chem Biol . 2024 Mar; 31(7):1247-1263.e16. PMID: 38537632
This study describes the identification and target deconvolution of small molecule inhibitors of oncogenic Yes-associated protein (YAP1)/TAZ activity with potent anti-tumor activity in vivo. A high-throughput screen (HTS) of 3.8...
3.
Enhanced Antitumor Efficacy of Radium-223 and Enzalutamide in the Intratibial LNCaP Prostate Cancer Model
Suominen M, Knuuttila M, Schatz C, Schlicker A, Vaaraniemi J, Sjoholm B, et al.
Int J Mol Sci . 2023 Feb; 24(3). PMID: 36768509
Radium-223 dichloride and enzalutamide are indicated for metastatic castration-resistant prostate cancer and their combination is currently being investigated in a large phase 3 clinical trial. Here, we evaluated the antitumor...
4.
Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study
Santin A, Vergote I, Gonzalez-Martin A, Moore K, Oaknin A, Romero I, et al.
Int J Gynecol Cancer . 2022 Dec; 33(4):562-570. PMID: 36564099
Objectives: Anetumab ravtansine is an antibody-drug conjugate consisting of a fully human anti-mesothelin monoclonal antibody conjugated to cytotoxic maytansinoid tubulin inhibitor DM4. Mesothelin is highly expressed in ovarian cancer. This...
5.
Immunostimulatory effects of targeted thorium-227 conjugates as single agent and in combination with anti-PD-L1 therapy
Lejeune P, Cruciani V, Berg-Larsen A, Schlicker A, Mobergslien A, Bartnitzky L, et al.
J Immunother Cancer . 2021 Oct; 9(10). PMID: 34615703
Background: Targeted thorium-227 conjugates (TTCs) are an emerging class of targeted alpha therapies (TATs). Their unique mode of action (MoA) is the induction of difficult-to-repair clustered DNA double-strand breaks. However,...
6.
Darolutamide Potentiates the Antitumor Efficacy of a PSMA-targeted Thorium-227 Conjugate by a Dual Mode of Action in Prostate Cancer Models
Hammer S, Schlicker A, Zitzmann-Kolbe S, Baumgart S, Hagemann U, Scholz A, et al.
Clin Cancer Res . 2021 May; 27(15):4367-4378. PMID: 34035067
Purpose: Androgen receptor (AR) inhibitors are well established in the treatment of castration-resistant prostate cancer and have recently shown efficacy also in castration-sensitive prostate cancer. Although most patients respond well...
7.
First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors
Yap T, Tan D, Terbuch A, Caldwell R, Guo C, Goh B, et al.
Cancer Discov . 2020 Sep; 11(1):80-91. PMID: 32988960
Targeting the ataxia telangiectasia and RAD3-related (ATR) enzyme represents a promising anticancer strategy for tumors with DNA damage response (DDR) defects and replication stress, including inactivation of ataxia telangiectasia mutated...
8.
Investigating the concordance in molecular subtypes of primary colorectal tumors and their matched synchronous liver metastasis
Schlicker A, Ellappalayam A, Beumer I, Snel M, Mittempergher L, Diosdado B, et al.
Int J Cancer . 2020 Apr; 147(8):2303-2315. PMID: 32270478
To date, no systematic analyses are available assessing concordance of molecular classifications between primary tumors (PT) and matched liver metastases (LM) of metastatic colorectal cancer (mCRC). We investigated concordance between...
9.
The Impact of Cand1 in Prostate Cancer
Eigentler A, Tymoszuk P, Zwick J, Schmitz A, Pircher A, Kocher F, et al.
Cancers (Basel) . 2020 Feb; 12(2). PMID: 32059441
Evidence has accumulated asserting the importance of cullin-RING (really interesting new gene) ubiquitin ligases (CRLs) and their regulator Cullin-associated neural-precursor-cell-expressed developmentally down-regulated 8 (NEDD8) dissociated protein 1 (Cand1) in various...
10.
The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage-Inducing or Repair-Compromising Therapies in Preclinical Cancer Models
Wengner A, Siemeister G, Lucking U, Lefranc J, Wortmann L, Lienau P, et al.
Mol Cancer Ther . 2019 Oct; 19(1):26-38. PMID: 31582533
The DNA damage response (DDR) secures the integrity of the genome of eukaryotic cells. DDR deficiencies can promote tumorigenesis but concurrently may increase dependence on alternative repair pathways. The ataxia...